靶向药物在HER2阳性乳腺癌患者化疗中的应用价值研究

Application Value of Targeted Drugs in Chemotherapy of HER2-Positive Breast Cancer Patients

目的探究靶向药物在表皮生长因子受体2(epidermal growth factor receptor 2,HER2)阳性乳腺癌患者化疗中的应用价值。方法将定西市人民医院2022年4—10月收治的50例HER2阳性乳腺癌患者按随机数字表法分为对照组(25例)与试验组(25例),对照组采用CEF新辅助化疗,试验组在对照组基础上加用靶向药物治疗。比较两组患者治疗效果、不良反应发生情况以及外周血角蛋白信使RNA(peripheral blood keratin messenger RNA,CK19mRNA)水平情况。结果试验组治疗总有效率高于对照组(96.00%vs.72.00%)(P<0.05);试验组不良反应总发生率高于对照组(16.00%vs.8.00%),但差异无统计学意义(P>0.05);治疗前,两组患者CK19mRNA水平比较,差异无统计学意义(P>0.05);治疗后,与对照组相比,试验组CK19mRNA水平较低(P<0.05)。结论在HER2阳性乳腺癌患者化疗中应用靶向药物可有效提升患者的治疗效果,改善CK19mRNA水平,安全有效。

Objective To explore the application value of targeted drugs in chemotherapy of epidermal growth factor receptor 2(HER2)positive breast cancer patients.Methods A total of 50 patients with HER2 positive breast cancer admitted to Dingxi People's Hospital from April to October 2022 were randomly divided into control group(25 cases)and trial group(25 cases),the control group was treated with CEF neoadjuvant chemotherapy,and the experimental group was treated with CEF neoadjuvant chemotherapy plus targeted drugs,the therapeutic effect,adverse reaction and CK19 mrna level in peripheral blood keratin messenger RNA(CK19 mrna)were compared between the two groups.Results The total effective rate of experimental group was higher than that of control group(96.00%vs.72.00%)(P<0.05).The total incidence of adverse reactions in experimental group was higher than that in control group(16.00%vs.8.00%),but the difference was not statistically significant(P>0.05).The CK19 mrna levels in the two groups compared,the difference was not statistically significant(P>0.05).After treatment,the CK19 mrna levels in the experimental group were lower than those in the control group(P<0.05).Conclusion The application of targeted drugs in the chemotherapy of HER2 positive breast cancer patients can effectively improve the therapeutic effect of patients and improve the level of CK19 mrna,which is safe and effective.